Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

46.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.5K
Retroviruses02:33

Retroviruses

12.6K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.6K
Subviral Agents01:29

Subviral Agents

76
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
76
Viral Mutations00:36

Viral Mutations

32.7K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>YoyoMut</i>: Interactive Exploration of SARS-CoV-2 Mutation Fixation and Reversion Through Time.

Life (Basel, Switzerland)·2026
Same author

On the Use of Immunoglobulins for Pre-exposure Prophylaxis Against COVID-19 in Immunocompromised Patients.

Infection and drug resistance·2026
Same author

Special Issue "Influenza Viruses: Infection and Genomics".

International journal of molecular sciences·2026
Same author

Convalescent plasma for COVID-19: planning for the next pandemic using the worldwide experience.

Clinical microbiology reviews·2025
Same author

A Rapid Systematic Review of U.S. Food and Drug Administration-authorized COVID-19 Treatments.

Open forum infectious diseases·2025
Same author

The Emergence of Escape Mutations in COVID-19 Following Anti-Spike Monoclonal Antibody Treatment: How Do We Tackle It?

Infection and drug resistance·2025

Related Experiment Video

Updated: Aug 20, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.4K

Molnupiravir: From Hope to Epic Fail?

Daniele Focosi1

  • 1North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.

Viruses
|November 24, 2022
PubMed
Summary

Molnupiravir, an oral antiviral for COVID-19 outpatients, shows reduced clinical efficacy and potential mutagenicity risks. Alternative treatments are now recommended over molnupiravir for better patient outcomes.

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • Molnupiravir was the first oral antiviral approved for COVID-19 outpatients.
  • It demonstrated high sales and maintained in vitro effectiveness against Omicron sublineages.
  • Recent findings indicate significant concerns regarding its clinical efficacy and safety.

Purpose of the Study:

  • To evaluate the current clinical utility and safety profile of molnupiravir.
  • To assess the risks associated with molnupiravir use, including variant emergence and mutagenicity.
  • To provide recommendations for alternative COVID-19 outpatient treatments.

Main Methods:

  • Review of recent clinical data and in vitro studies on molnupiravir.
  • Analysis of reported adverse events and potential for SARS-CoV-2 variant evolution.
Keywords:
EID-1931MK4882NHCSARS-CoV-2molnupiravirmutagenicity

More Related Videos

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

1.5K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

13.9K

Related Experiment Videos

Last Updated: Aug 20, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.4K
Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

1.5K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

13.9K
  • Comparative assessment of molnupiravir against other available antiviral therapies.

    • Main Results:

    • Molnupiravir is associated with diminished clinical effectiveness in real-world settings.
    • Concerns exist regarding its potential to generate new SARS-CoV-2 variants of concern.
    • Long-term mutagenicity risks in humans are a significant consideration, particularly for immunocompromised patients.

    Conclusions:

    • Molnupiravir's clinical efficacy appears compromised, necessitating a re-evaluation of its use.
    • The risks of inducing viral mutations and potential human mutagenicity outweigh its benefits in certain populations.
    • Alternative oral antiviral medications should be prioritized for the treatment of COVID-19 outpatients.